It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

1

Manuscript word count: 2418 Display items: 4 Supplementary file: yes Abstract word count: 246 Reference count: 54

**Title:** Gaps in the phenotype descriptions of ultra-rare genetic conditions: review and multicenter consensus reporting guidelines

### Author list:

Ali AlMail<sup>1,2</sup>, Ahmed Jamjoom<sup>1,3</sup>, Amy Pan<sup>4</sup>, Min Yi Feng<sup>4</sup>, Vann Chau<sup>3,5</sup>, Alissa D'Gama<sup>6,7,8</sup>, Katherine Howell<sup>9,10</sup>, Nicole S.Y. Liang<sup>4,11</sup>, Amy McTague<sup>12,13</sup>, Annapurna Poduri<sup>6,14</sup>, Kimberly Wiltrout<sup>6,14</sup>, IPCHiP Executive Committee\*, Anne S. Bassett<sup>15</sup>, John Christodoulou<sup>10</sup>, Lucie Dupuis<sup>11</sup>, Peter Gill<sup>3</sup>, Tess Levy<sup>16</sup>, Paige Siper<sup>16</sup>, Zornitza Stark<sup>10,17,18</sup>, Jacob A.S. Vorstman<sup>15,19</sup>, Catherine Diskin<sup>3</sup>, Natalie Jewitt<sup>3</sup>, Danielle Baribeau<sup>15,20,\*\*</sup>, Gregory Costain<sup>2,3,4,11,\*\*</sup>

<sup>1</sup>Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

<sup>2</sup>Program in Genetics & Genome Biology, SickKids Research Institute, Toronto, Canada

<sup>3</sup>Department of Paediatrics, University of Toronto, Toronto, Canada

<sup>4</sup>Department of Molecular Genetics, University of Toronto, Toronto, Canada

<sup>5</sup>Division of Neurology, Hospital for Sick Children, Toronto, Canada

<sup>6</sup>Department of Neurology, Boston Children's Hospital, Boston, MA, USA

<sup>7</sup>Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA

<sup>8</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA

<sup>9</sup>Department of Neurology, Royal Children's Hospital, Melbourne, Australia

<sup>10</sup>Murdoch Children's Research Institute, Melbourne, Australia

<sup>11</sup>Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, Canada

<sup>12</sup>Department of Neurology, Great Ormond Street Hospital, London, UK

<sup>13</sup>Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK

<sup>14</sup>Department of Neurology, Harvard Medical School, Boston, MA, USA

<sup>15</sup>Department of Psychiatry, University of Toronto, Toronto, Canada

<sup>16</sup>Division of Psychiatry, Ichan School of Medicine at Mount Sinai, New York City, New York, United States of America

<sup>17</sup>Department of Paediatrics, University of Melbourne, Melbourne, Australia

<sup>18</sup>Victorian Clinical Genetics Service, Melbourne, Australia

<sup>19</sup>Department of Psychiatry, Hospital for Sick Children, Toronto, Canada

<sup>20</sup>Autism Research Centre, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Canada

**\*IPCHiP Executive Committee members:** Nancy C Andrews, Alan H Beggs, John Christodoulou, J Helen Cross, Christian R Marshall, Kathryn N North, Stephen W Scherer, Neil J Sebire, Piotr Sliz

**\*\*Contact information:** Danielle Baribeau, MD, PhD, FRCPC, E-mail: <u>dbaribeau@hollandbloorview.ca</u>; Gregory Costain, MD, PhD, FRCPC, E-mail: <u>gregory.costain@sickkids.ca</u>

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

### ABSTRACT

**Background:** Genome-wide sequencing and genetic matchmaker services are propelling a new era of genotype-first ascertainment of novel genetic conditions. The degree to which reported phenotype data in discovery-focused studies address informational priorities for clinicians and families is unclear.

**Methods:** We identified reports published from 2017-2021 in ten genetics journals of novel Mendelian disorders ascertained genotype-first. We adjudicated the quality and detail of the phenotype data via 46 questions pertaining to six priority domains: (I) Development, cognition, and mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy. For a subset of articles, all subsequent published follow-up case descriptions were identified and assessed in a similar manner. A modified Delphi approach was used to develop consensus reporting guidelines, with input from content experts across four countries.

**Results:** In total, 200 of 3243 screened publications met inclusion criteria. Relevant phenotypic details across each of the six domains were rated superficial or deficient in >87% of papers. For example, less than 10% of publications provided details regarding neuropsychiatric diagnoses and "behavioural issues", or about the type/nature of feeding problems. Follow-up reports (n=95) rarely addressed the limitations of the original reports. Reporting guidelines were developed for each domain.

**Conclusion:** Phenotype information relevant to clinical management, genetic counseling, and the stated priorities of patients and families is lacking for many newly described genetic diseases. Use of the proposed guidelines could improve phenotype reporting in the genomic era.

#### **KEYWORDS**

Phenotype, Ultra-rare genetic conditions, Genome sequencing, Natural history, Mendelian genetic diseases

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

# 1 INTRODUCTION

2 Genome-wide sequencing and genetic matchmaker services have created a new paradigm for 3 Mendelian disorder delineation.<sup>1-3</sup> Compared to prior decades, when syndrome identification was 4 predominantly phenotype driven, there is now an increasing focus on genotype-first ascertainment 5 and on generating functional evidence or usage of non-human model systems to support the 6 disease-variant/gene association. There are no well-defined nor broadly accepted minimum 7 standards for phenotype descriptions of putative novel disorders with multisystem manifestations 8 and/or a neurodevelopmental component. Variability in the consistency of phenotyping and 9 describing of findings is problematic. This variability can be exacerbated by individual sites each 10 contributing only a single patient to an international case-series study, or the extraction of 11 phenotype data from laboratory test requisitions.

12

13 After a first description of a novel Mendelian disorder is published, patients soon thereafter begin to be diagnosed via clinical genome-wide sequencing.<sup>4-6</sup> These individually ultra-rare<sup>7</sup> conditions 14 are collectively important contributors to the burden of genetic disease in the population.<sup>8</sup> The 15 16 typical benefits of a molecular genetic diagnosis<sup>7,9</sup> are attenuated when there is limited information available to inform genotype-phenotype correlation, natural history, prognostication, and 17 18 anticipatory care. A key consideration in the assessment of ultra-rare conditions for potential 19 "precision therapy" development is the degree to which the patient's clinical trajectory can be 20 anticipated.<sup>10,11</sup> Families who are amongst the first to receive a diagnosis of an ultra-rare genetic disorder have endorsed frustration with the perceived lack of information and support.<sup>12,13</sup> 21 22 Similarly, clinicians face the same informational barrier, which impacts their abilities to care for 23 and counsel patients and their families.<sup>14</sup>

24

Published expert opinions, survey data, reviews, and data from patient and family focus groups
 highlight key informational areas germane to the natural history of ultra-rare genetic diseases.<sup>14-24</sup>

27 We assessed the breadth and depth of phenotype reporting in contemporary descriptions of novel

28 Mendelian genetic diseases across six priority domains: (I) Development, cognition, and mental

health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and

30 quality of life; (V) Adulthood; and (VI) Epilepsy. We also assessed in a similar manner follow-up

31 reports appearing in the years following an initial report. These findings provided the impetus for,

32 and guided the development of, the proposed new PHELIX (PHEnotype LIsting fiX) reporting

33 guideline checklists.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

# 34 MATERIALS AND METHODS

## 35 Systematic review

36 We utilized DistillerSR Version 2.35 for searching, screening, and data extraction (DistillerSR Inc, 37 2022; accessed January 2022 – January 2023). We identified all first reports of novel genetic 38 conditions discovered through genotype-first ascertainment that result in multisystem and/or 39 neurodevelopmental phenotypes, which were published in one of ten genetics journals (American 40 Journal of Human Genetics, American Journal of Medical Genetics Part A, Clinical Genetics, 41 European Journal of Human Genetics, Genetics in Medicine, Genome Medicine, Human 42 Molecular Genetics, Journal of Medical Genetics, Nature Genetics, PLoS Genetics) during a 5-43 year period (1 January 2017 - 31 December 2021). The search executed on January 3, 2022, 44 identified 3,243 articles (Supplementary Table 1; Supplementary Figure 1). Exclusion criteria 45 were: (i) prenatal or neonatal lethal phenotype, (ii) case report or description of a single family, 46 (iii) new gene for a known clinical syndrome (e.g., Joubert syndrome, Noonan syndrome), (iv) 47 chromosome disorder with non-recurrent breakpoints that did not definitively implicate a specific 48 gene, (v) potential genotype-phenotype expansion rather than a novel disorder. We also excluded 49 large-scale gene discovery efforts in populations with common complex diseases and/or clinical testing laboratory cohort studies, where the *a priori* expectation for detailed phenotype 50 51 descriptions was low. After both title and abstract screening and full-text review stages, n=200 52 reports describing 199 distinct monogenic conditions met the inclusion criteria (two reports of a 53 novel condition were published at the same time; Supplementary Figure 1). For the subset of 25 54 genetic conditions first described in 2017, we performed an additional search using DistillerSR on 55 June 1, 2022 (Supplementary Table 1) to identify subsequent published case descriptions (total 56 n=95; Supplementary Figure 2). Reference review and additional internet searching did not 57 identify any other "follow-up" reports.

58

## 59 Data extraction and analysis

For each published article (n=295), study team members (authors A.A., A.J., A.P., M.Y.F.) 60 61 adjudicated the phenotype data pertaining to six priority domains [(I) Development, cognition, and 62 mental health; (II) Feeding and growth; (III) Medication use and treatment history; (IV) Pain, sleep, and quality of life; (V) Adulthood; and (VI) Epilepsy] using a custom designed data 63 64 extraction form (Supplementary Tables 3, 5, 6). Domains I-VI were included based on the study 65 team's clinical experience and review of the aforementioned published expert opinions, survey data, reviews, and data from patient and family focus groups.<sup>14-24</sup> Data for Domains V-VI were 66 67 extracted separately from Domains I-IV. The total 46-item form was developed by members of the 68 study team (authors A.A., A.J., C.D., N.J., D.B., G.C.) with clinical expertise in medical genetics, 69 psychiatry, development, general paediatrics, paediatric palliative care, paediatric complex care, 70 and paediatric hospitalist medicine. Each domain was associated with multiple issue-specific 71 items. A separate overall qualitative assessment of reporting quality ("strong", "adequate", 72 "superficial/deficient", "absent", or "not applicable") was also assigned for Domains I-IV. Descriptive statistics were calculated using Microsoft Excel. 73

74

### 75 Development of phenotype reporting guidelines through a modified Delphi process

76 Medical experts from member institutions of the International Precision Child Health Partnership

- 77 (IPCHiP) participated in a modified Delphi process.<sup>25</sup> IPCHiP institutions included: Murdoch
- 78 Children's Research Institute/Royal Children's Hospital (Melbourne, Australia), The Hospital for
- 79 Sick Children (SickKids®; Toronto, Ontario, Canada), University College London/Greater

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

80 Ormond Street Hospital (London, United Kingdom), and Boston Children's Hospital (Massachusetts, USA).<sup>26,27</sup> At the suggestion of the original study team members, additional 81 expertise was sought in: (i) neuropsychological assessment and cognitive phenotyping (via Seaver 82 Autism Center for Research and Treatment; New York, USA),<sup>28-30</sup> and (ii) adult phenotyping (via 83 University Health Network; Toronto, Ontario, Canada).<sup>31,32</sup> Authors J.C., L.D., P.G., T.L., P.S., 84 85 Z.S., J.A.S.V., C.D., N.J., D.B. contributed to the initial refinement of guidelines for Domains I-86 V. We sent out three electronic surveys to the above authors (minimum engagement rate >50%) 87 over a five-month period to define and prioritize the reporting criteria. We then hosted an online 88 meeting that incorporated independent voting on inclusion/exclusion of each draft item. The 89 meeting was recorded, to allow for asynchronous viewing by those expert volunteers who were 90 unable to attend in real-time. Authors V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W. contributed to 91 the initial refinement of guidelines for Domain VI (Epilepsy). Similarly, we used a series of two 92 electronic surveys to define and prioritize the reporting criteria. All authors reviewed, revised, and 93 ultimately approved the reporting guideline checklists for Domains I-VI reported herein. The 94 guideline checklists will be uploaded to the EOUATOR (Enhancing the QUAlity and 95 Transparency Of health Research) Network website (https://www.equator-network.org/) as the PHELIX General (Table 1) and the PHELIX Epilepsy checklists (Table 2). 96

It is made available under a CC-BY-NC 4.0 International license.

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

### 97 **RESULTS**

#### 98 Contemporary descriptions of new syndromes are often lacking in phenotype details

99 The 200 reports of 199 newly discovered genetic disorders included phenotype descriptions for a 100 total of 1,856 study participants (median: 7/report, range 2-42). Features of the reports (year and 101 journal of publication) and of the participants (age) are summarized in Supplementary Tables 2-102 3). The overall qualitative assessment of reporting was deemed "superficial/deficient" or "absent" 103 in 87% (Domain I: Development, cognition, and mental health) to 98% (Domain IV: Pain, sleep, 104 and quality of life) of papers (Figure 1). Five (2.5% of 200) reports were deemed "strong" in any 105 single domain (pertaining to the genetic conditions associated with variants in the genes ADARB1<sup>33</sup>, GNAI1<sup>34</sup>, NCAPG2<sup>35</sup>, PCDHGC4<sup>36</sup>, and SPTBN1<sup>37</sup>). No reports were deemed 106 107 "strong" in their reporting across each of Domains I-IV. The year and journal of publication were 108 not associated with overall quality assessment of phenotype reporting (data not shown).

109

110 Item-specific data supported the overall qualitative assessments of reporting quality (Figure 2, 111 Supplementary Table 3, Supplementary Figures 3-4). While 97% of papers mentioned 112 developmental concerns in study participants, 21% provided details about cognitive abilities for 113 all the participants and a sole paper<sup>38</sup> reported results from formal cognitive assessments for all 114 participants (Figure 2a, Supplementary Table 4). A common issue was that individuals were 115 identified as having "developmental delay" without further elaboration. Similarly, of the papers 116 that reported neuropsychiatric and behavioural issues in study participants, less than 5% of papers 117 provided details for all participants regarding type/diagnosis, symptom severity, and/or nature of 118 the assessments (Figure 2a, Supplementary Table 3). Of the papers that reported on the presence 119 of feeding difficulties (Figure 2b), 8% consistently reported on the type/nature of feeding issues 120 and current means of feeding (Figure 2b, Supplementary Table 3). Growth parameters at birth were 121 often reported, but 6% of papers reported on two or more growth measurements post-birth to allow 122 for assessment of growth trajectories (Figure 2b, Supplementary Table 4). Nearly half of all papers 123 made no mention of participants' medications or treatment trials, or of the absence thereof (Figure 124 2c). The presence or absence of adverse effects of treatments were explicitly mentioned in just 125 21% of reports (Figure 2c).

126

127 Domain V (Adulthood) was assessed in the subset of reports that included at least one adult 128 individual (n=63; adult defined as age >=18 years) (Supplementary Figure 1; Supplementary Table

6). Domain VI (Epilepsy) was assessed in the subset of reports that included at least one study

participant with seizures/epilepsy (n=85) (Supplementary Figure 1; Supplementary Table 7).

131 Consistent with the findings regarding Domains I-IV, most items were inconsistently or never 132 reported (Supplementary Figures 3-4). For example, papers rarely described proxies for adult

functioning such as educational achievement or employment, nor the anti-seizure treatments for

- 134 individuals with epilepsy.
- 135

### 136 Follow-up reports do not consistently address initial gaps in phenotype descriptions

137 Regarding the 25 genetic conditions first described in 2017, the 95 "follow-up" reports included

138 phenotype descriptions for an additional 334 study participants (median: 1 per report, range 1-25).

139 The overall qualitative assessment of reporting was similarly classified as "absent" or

- 140 "superficial/deficient" in 81% (Domain III: Medication use and treatment history) to 99% (Domain
- 141 IV: Pain, sleep, and quality of life) of papers (Figure 1, Supplementary Table 4), with no significant
- 142 differences between the original and the follow-up reports. Eleven reports were deemed "strong"

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

143 in any single domain (pertaining to the genetic conditions associated with variants in the eight

- 144 genes  $CAMK2A^{39}$ ,  $CAMK2B^{39,40}$ ,  $DHX30^{41}$ ,  $OTUD6B^{42}$ ,  $PPP3CA^{43}$ ,  $UBTF^{44,45}$ ,  $WDR26^{46,47}$ , and 145  $YYI^{48}$ ). No reports were deemed "strong" in their reporting across each of domains I-IV. Item-146 specific data are summarized in Supplementary Table 4
- specific data are summarized in Supplementary Table 4.
- 147

# 148 **Consensus phenotype reporting guidelines**

Guideline checklists to enhance the reporting of phenotype data for ultra-rare genetic conditions were developed through a modified Delphi process<sup>25</sup> and informed by the findings above

151 (Supplementary Table 8). Specifically, items were included based on their superficial/deficient

- reporting in the literature to date, and on the recommendations of expert collaborators as being
- 153 data that are both important to capture and feasible to obtain by researchers. The finalized checklist 154 of 33 items across 9 categories is presented in Table 1 (PHELIX General). To showcase how these
- 155 guidelines could be expanded over time, additional items specific to epilepsy phenotype reporting
- are listed in Table 2 (PHELIX\_Epilepsy). Extended versions with examples are provided in
- 157 Supplementary Tables 9-10.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

## 158 **DISCUSSION**

159 Our results reveal that phenotype information relevant to clinical management, genetic counseling,

and the stated priorities of patients and families, is lacking for many newly described genetic

161 diseases. Although most published reports acknowledged the key phenotype domains assessed, 162 few original or follow-up reports included clinically relevant details. To address this issue, we

162 rew original of follow-up reports included clinically relevant details. To address this issue, we 163 propose reporting guideline checklists for use by researchers and journals. Use of these guidelines

- 164 could improve phenotype reporting in the era of genotype-first and matchmaker service-driven
- 165 reports of novel syndromes. Decision making about precision genetic or other therapy
- 166 development, including the potential for n=1 trials, may be contingent on our understanding (or
- 167 lack thereof) of the natural history of a given ultra-rare genetic disease.<sup>10,11,49</sup>
- 168

169 Reasons for under-reporting phenotype data are likely multiple and complex. First, these data may

170 not be readily available to the referring clinician or laboratory collaborators, and "phenotyping is 171 hard,"50 especially for older individuals with extensive past histories. Review of lifetime medical 172 records, and/or a brief, targeted interview with patients and/or their caregiver(s), should be 173 sufficient to gather most of the information outlined in Tables 1-2. Second, these data may not be 174 requested by the coordinating research team that is leading the publication effort. In our 175 experience, many groups design their own data collection forms that ask for no or only general 176 details regarding issues outside of that group's specific phenotype(s) of interest. Third, unlike for 177 example DNA sequencing methods, there are no defined minimum reporting standards for 178 phenotyping to guide peer reviewers and journal editors. Finally, there may be a belief that 179 phenotype reporting in initial descriptions of novel genetic diseases is less important than establishing an association between variation in the gene and (any) disease phenotype. Although 180 181 the hope may be that future reports will then describe many more individuals and include detailed 182 phenotype data, we did not find evidence that this is consistently happening in practice in a timely 183 manner.

184

185 We recognize several limitations of our review and guideline development methods. We selected 186 only ten top-tier genetics journals for our systematic review. The generalizability of our findings 187 to reports published in other specialty-specific or organ system-specific journals is unclear. Out of 188 necessity given the lack of validated tools, we created a new data collection questionnaire to assess 189 the reporting of phenotype data and relied on subjective assessments from raters for some items. 190 We selected broad phenotype domains based on our combined clinical experiences and the 191 published literature. Ours was a paediatrics-focused effort, reflecting the phenotypes that are 192 currently driving most Mendelian gene discovery efforts. Other groups may develop and add-on 193 reporting criteria for additional specific phenotype elements, as we did for epilepsy, and continue 194 to refine the general adult phenotype elements (Table 2). We also restricted our initial focus to 195 cross-sectional reporting, and additional guidance will be needed for evaluating within-individual 196 natural history. Finally, our reporting guidelines have not yet been applied prospectively to assess 197 feasibility and utility.

198

We propose minimum standards for phenotype descriptions of putative novel disorders with multisystem manifestations and/or a neurodevelopmental component in children. Further refinement of our proposed reporting guidelines is an important consideration. Collecting additional input from key stakeholders (e.g., rare disease organizations, journal editors) should be

203 coupled with attempts to better integrate technologies for systematic phenotype collection and data

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

sharing.<sup>21,51</sup> Improved reporting of phenotype aspects like craniofacial morphology ("dysmorphic features")<sup>52</sup> could help with interpreting variants of uncertain significance and assessing phenotypic "fit".<sup>53,54</sup> The aim of the PHELIX guideline checklists is to decrease the variability in the consistency of phenotyping and description of findings, and thereby enhance the ongoing clinical care of individuals with genetic conditions.

10

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

# 209 **Table 1.** Phenotype reporting checklist (PHELIX\_General version 1.0).

Phenotype	Recommendati	Specific Recommendation For Inclusion In Report		
Category	on Category			
1. Development and Cognition	Strongly recommended	i. Standard and specific diagnostic term(s) for cognitive or developmental issue(s)		
		ii. Level of cognitive functioning or degree of developmental delay		
		iii. Age of attaining major milestones		
		iv. Quantitative results from psychometric testing OR explicit acknowledgement that these results were not available		
	Optional, but encouraged	v. Narrative summary describing progression / change in cognitive or development issue(s) over time.		
2. Behaviour and Neuropsychiatric	Strongly recommended	i. Standard and specific diagnostic term(s) for behavioural issues		
Conditions	Optional, but encouraged	ii. Reported functional impact of behavioural/psychiatric condition		
		iii. Age at diagnosis and/or age at first concern for behavioural issues		
		iv. Impact of treatments / interventions, as reported by individuals, families, and/or clinicians		
3. Other Medical	Strongly	i.Major medical conditions		
Conditions	recommended	ii. Presence or absence of issues in the following areas (if potentially associated with the condition under study):		
		<ul> <li>Visual acuity and field of vision</li> <li>Hearing ability</li> <li>Speech/communication styles</li> </ul>		
		<ul><li>Continence/toileting</li><li>Ambulation</li></ul>		
4. Feeding Issues	Strongly	i. Functional impact of feeding issues		
	recommended	ii. Current feeding method (e.g., oral, gastrostomy tube)		
	Optional, but encouraged	iii. Age at first concern for feeding issues		
		iv. Interventions and supports for feeding issues (e.g., feeding tube support)		
5. Growth	Strongly recommended	i. Birth growth measurements AND gestational age- corrected centiles		

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

11

		ii. Growth measurements (absolute values and z- scores) at two or more post-birth timepoints (where possible)		
6. Medication and	Optional, but	i. Details of efficacious treatment(s)		
Treatment History	encouraged	ii. Severe adverse events / reactions		
7. Pain, Sleep, and	Optional, but	i. Presence or absence of pain / neuroirritability		
Quality of Life	encouraged	ii. Presence or absence of abnormal sleep patterns / sleep disturbance		
		iii. Qualitative description of proxies for quality of life, via patient and/or caregiver report		
		iv. Direct assessment of quality of life using established measure(s), via patient and/or caregiver report		
8. Indicators of	Strongly	i. Age at which the adult was last seen/phenotyped		
adult functional outcome	recommended	ii. Description of educational achievement		
		iii. Nature of any employment (past and/or present)		
	Optional, but encouraged	iv. Relationship status (past and/or present)		
		v. Reproductive history		
9.Other	ther Strongly i. Confirmation of informed conse recommended the research study and to include t information, for each participant			
		ii. Distinguish between "not assessed" and "assessed and not present," for every aspect of a phenotype described in the report and for each participant		
		<ul><li>iii. Description of how phenotyping was performed</li><li>(e.g., direct assessment by study team member(s),</li><li>review of medical records, information provided on</li><li>testing requisition), for each participant</li></ul>		
		iv. Use of standard phenotype labels (e.g., HPO, ICD- 11) to standardize reporting, for each participant.		
		v. [For deceased participants] Cause of death		

211 Abbreviations: HPO, Human Phenotype Ontology; ICD-11, International Classification of

<sup>212</sup> Diseases 11th Revision

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

- 12
- 213 **Table 2.** Phenotype reporting recommendations for unprovoked seizures/epilepsy in individuals
- 214 with newly described multisystem and/or neurodevelopmental Mendelian disorders
- 215 (PHELIX\_Epilepsy version 1.0).

Phenotype	Recommendation	Specific Recommendation For Inclusion In Report		
Subcategory 1. Epilepsy syndrome and severity	Category Strongly recommended	<ul> <li>i. Seizure type(s) (per ILAE)</li> <li>ii. Epilepsy syndrome(s) (per ILAE)</li> <li>iii. Findings that support the diagnosis of the epilepsy syndrome(s) (e.g., specific EEG findings)</li> <li>iv. Seizure frequency at last clinical assessment</li> <li>v. Qualitative description of overall epilepsy severity</li> </ul>		
	Optional, but encouraged	vi. Number of seizures requiring hospitalization in specific timeframe (e.g., last year)		
2. Pharmacological interventions	Strongly recommended Optional, but encouraged	<ul> <li>i. Current and past medication name(s)</li> <li>ii. Perceived impact on seizure control</li> <li>iii. Dose</li> <li>iv. Duration of treatment trial</li> </ul>		
3. Non-	Strongly	<ul><li>v. Adverse effects/events due to the intervention</li><li>i. Intervention / procedure details (e.g., ketogenic</li></ul>		
pharmacological interventions	Recommended	diet, neurosurgery) ii. Perceived impact on seizure control		
	Optional, but encouraged	iii. Adverse effects/events due to the intervention		
4. Brain imaging and EEG findings	Strongly recommended	<ul><li>i. Brain imaging findings (including age(s) at time of study)</li><li>ii. EEG findings (including age(s) at time of study)</li></ul>		
	Optional, but encouraged	<ul> <li>iii. Clarification if brain imaging and/or EEG data were directly reviewed by members of the study team (versus only report details extracted from medical record)</li> </ul>		
5. Other	Optional, but encouraged	<ul> <li>i. Narrative summary of the progression of the individual's seizure(s)/epilepsy phenotype over time</li> <li>ii. Narrative summary of the progression of the individual's non-epilepsy phenotype over time (e.g., see PHELIX_General guidelines)</li> </ul>		

216 Abbreviations: EEG, electroencephalogram; ILAE, International League Against Epilepsy

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

#### 217 ACKNOWLEDGMENTS

- 218 Funding was provided by the SickKids Research Institute, the Canadian Institutes of Health
- 219 Research (Funding Reference Number: PJT186240), and the University of Toronto McLaughlin
- 220 Centre. IPCHiP is supported in part by SickKids Foundation donors including Jamie and Patsy
- 221 Anderson and the Feiga Bresver Academic Foundation. D.B. also acknowledges the support of her
- 222 research time at Holland Bloorview by the Arthur Family Foundation. J.A.S.V. holds the SickKids
- 223 Psychiatry Associates Chair in Developmental Psychopathology at The Hospital for Sick Children.
- 224 Research conducted at the Murdoch Children's Research Institute was supported by the Victorian 225 Government's Operational Infrastructure Support Program. The Chair in Genomic Medicine
- 226 awarded to J.C. is generously supported by The Royal Children's Hospital Foundation. These
- 227 funders played no role in study design, data collection, analysis and interpretation of data, or the
- 228 writing of this manuscript.
- 229

#### 230 **CRediT AUTHOR STATEMENT**

- Conceptualization: D.B., G.C. 231
- 232 Methodology: A.A., A.J., C.D., N.J., D.B., G.C.
- 233 Software: N/A
- 234 Validation: A.A., A.J., A.P., M.Y.F., G.C.
- 235 Formal analysis: A.A.
- 236 Investigation: A.A., A.J., A.P., M.Y.F., V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W., A.S.B., J.C.,
- 237 L.D., P.G., T.L., P.S., Z.S., J.A.S.V., C.D., N.J., D.B., G.C.
- 238 Resources: G.C.
- 239 Data curation: N/A
- 240 Writing – original draft: A.A., A.J., D.B., G.C.
- 241 Writing - review & editing: A.P., M.Y.F., V.C., A.D., K.H., N.S.Y.L., A.T., A.P., K.W., A.S.B.,
- 242 J.C., L.D., P.G., T.L., P.S., Z.S., J.A.S.V., C.D., N.J.
- 243 Visualization: A.A., A.J.
- 244 Supervision: L.D., P.G., G.C.
- 245 Project administration: A.A., A.J., D.B., G.C.
- 246 Funding acquisition: G.C.
- 247

#### 248 **DECLARATION OF INTERESTS**

- 249 D.B. has received research funds from MapLight Therapeutics. K.W. has consulted for Stoke 250
- Therapeutics. J.A.S.V. has served as a consultant for NoBias Therapeutics Inc. and has received
- 251 speaker fees for Henry Stewart Talks Ltd. These relationships did not influence content of this
- 252 manuscript but are disclosed for potential future considerations. The remaining authors declare no
- 253 financial or non-financial competing interests.
- 254

#### 255 DATA AVAILABILITY STATEMENT

- 256 The datasets analysed during the current study are available from the corresponding authors on
- 257 reasonable request.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

258		REFERENCES
259		
260 261	1.	Bamshad MJ, Nickerson DA, Chong JX. Mendelian Gene Discovery: Fast and Furious with No End in Sight. Am J Hum Genet. 2019;105(3):448-455.
262 263	2.	Boycott KM, Hartley T, Biesecker LG, et al. A Diagnosis for All Rare Genetic Diseases: The Horizon and the Next Frontiers. Cell. 2019;177(1):32-37.
264	3.	Boycott KM, Azzariti DR, Hamosh A, Rehm HL. Seven years since the launch of the
265		Matchmaker Exchange: The evolution of genomic matchmaking. Hum Mutat.
266		2022;43(6):659-667.
267	4.	Bick D, Jones M, Taylor SL, Taft RJ, Belmont J. Case for genome sequencing in infants
268		and children with rare, undiagnosed or genetic diseases. J Med Genet. 2019;56(12):783-
269		791.
270	5.	Australian Genomics Health Alliance Acute Care F, Lunke S, Eggers S, et al. Feasibility
271		of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected
272		Monogenic Conditions in the Australian Public Health Care System. JAMA.
273		2020;323(24):2503-2511.
274	6.	Costain G, Cohn RD, Scherer SW, Marshall CR. Genome sequencing as a diagnostic test.
275	_	CMAJ. 2021;193(42):E1626-E1629.
276	7.	Costain G, Walker S, Marano M, et al. Genome Sequencing as a Diagnostic Test in
277		Children With Unexplained Medical Complexity. JAMA Netw Open.
278	0	2020;3(9):e2018109.
279	8.	Haque B, Khan T, Ushcatz I, et al. Contemporary aetiologies of medical complexity in
280	0	children: a cohort study. Arch Dis Child. 2023;108(2):147-149.
281 282	9.	Costain G, Chow EW, Ray PN, Bassett AS. Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome. J Intellect Disabil Res.
282		2012;56(6):641-651.
283 284	10.	Pena LDM, Burrage LC, Enns GM, et al. Contributions from medical geneticists in
285	10.	clinical trials of genetic therapies: A points to consider statement of the American
285		College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(6):100831.
287	11.	Gleeson JG, Bennett CF, Carroll JB, et al. Personalized antisense oligonucleotides 'for
288		free, for life' - the n-Lorem Foundation. Nat Med. 2023;29(6):1302-1303.
289	12.	Fanos JH. New "first families": the psychosocial impact of new genetic technologies.
290		Genet Med. 2012;14(2):189-190.
291	13.	Lee W, Luca S, Costain G, et al. Genome sequencing among children with medical
292		complexity: What constitutes value from parents' perspective? J Genet Couns.
293		2022;31(2):523-533.
294	14.	Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of
295		physicians regarding the diagnosis of rare diseases: a questionnaire-based study in
296		Belgium. Orphanet J Rare Dis. 2019;14(1):99.
297	15.	Diskin C, Malik K, Gill PJ, et al. Research priorities for children with neurological
298		impairment and medical complexity in high-income countries. Dev Med Child Neurol.
299		2021.
300	16.	Nelson KE, Finlay M, Huang E, et al. Clinical characteristics of children with severe
301		neurologic impairment: A scoping review. J Hosp Med. 2023;18(1):65-77.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

302	17.	Gill PJ, Bayliss A, Sozer A, et al. Patient, Caregiver, and Clinician Participation in
303		Prioritization of Research Questions in Pediatric Hospital Medicine. JAMA Netw Open.
304	10	2022;5(4):e229085.
305	18.	Jacquemont S, Huguet G, Klein M, et al. Genes To Mental Health (G2MH): A
306		Framework to Map the Combined Effects of Rare and Common Variants on Dimensions
307		of Cognition and Psychopathology. Am J Psychiatry. 2022;179(3):189-203.
308	19.	Commission on Novel Technologies for Neurodevelopmental Copy Number V.
309		Neurodevelopmental copy-number variants: A roadmap to improving outcomes by
310		uniting patient advocates, researchers, and clinicians for collective impact. Am J Hum
311		Genet. 2022;109(8):1353-1365.
312	20.	Hanly C, Shah H, Au PYB, Murias K. Description of neurodevelopmental phenotypes
313		associated with 10 genetic neurodevelopmental disorders: A scoping review. Clin Genet.
314		2021;99(3):335-346.
315	21.	Jacobsen JOB, Baudis M, Baynam GS, et al. The GA4GH Phenopacket schema defines a
316		computable representation of clinical data. Nat Biotechnol. 2022;40(6):817-820.
317	22.	McTague A, Brunklaus A, Barcia G, et al. Defining causal variants in rare epilepsies: an
318		essential team effort between biomedical scientists, geneticists and epileptologists. Eur J
319		Med Genet. 2022;65(7):104531.
320	23.	Perlman P, Vorstman J, Hoang N, et al. Support to caregivers who have received genetic
321		information about neurodevelopmental and psychiatric vulnerability in their young
322		children: A narrative review. Clin Genet. 2023;104(2):163-173.
323	24.	Baribeau DA, Hoang N, Selvanayagam T, et al. Developmental implications of genetic
324		testing for physical indications. Eur J Hum Genet. 2022;30(11):1297-1300.
325	25.	Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research
326		reporting guidelines. PLoS Med. 2010;7(2):e1000217.
327	26.	Morton SU, Christodoulou J, Costain G, et al. Multicenter Consensus Approach to
328		Evaluation of Neonatal Hypotonia in the Genomic Era: A Review. JAMA Neurol.
329		2022;79(4):405-413.
330	27.	D'Gama AM, Mulhern S, Sheidley BR, et al. Evaluation of the feasibility, diagnostic
331		yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-
332		STEPS): an international, multicentre, pilot cohort study. Lancet Neurol. 2023;22(9):812-
333		825.
334	28.	Levy T, Lerman B, Halpern D, et al. CHAMP1 disorder is associated with a complex
335		neurobehavioral phenotype including autism, ADHD, repetitive behaviors and sensory
336		symptoms. Hum Mol Genet. 2022;31(15):2582-2594.
337	29.	Levy T, Foss-Feig JH, Betancur C, et al. Strong evidence for genotype-phenotype
338		correlations in Phelan-McDermid syndrome: results from the developmental
339		synaptopathies consortium. Hum Mol Genet. 2022;31(4):625-637.
340	30.	Tang L, Levy T, Guillory S, et al. Prospective and detailed behavioral phenotyping in
341		DDX3X syndrome. Mol Autism. 2021;12(1):36.
342	31.	Butcher NJ, Chow EW, Costain G, Karas D, Ho A, Bassett AS. Functional outcomes of
343		adults with 22q11.2 deletion syndrome. Genet Med. 2012;14(10):836-843.
344	32.	Malecki SL, Van Mil S, Graffi J, et al. A genetic model for multimorbidity in young
345		adults. Genet Med. 2020;22(1):132-141.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

346	33.	Tan TY, Sedmik J, Fitzgerald MP, et al. Bi-allelic ADARB1 Variants Associated with
347		Microcephaly, Intellectual Disability, and Seizures. Am J Hum Genet. 2020;106(4):467-
348		483.
349	34.	Muir AM, Gardner JF, van Jaarsveld RH, et al. Variants in GNAI1 cause a syndrome
350		associated with variable features including developmental delay, seizures, and hypotonia.
351		Genet Med. 2021;23(5):881-887.
352	35.	Khan TN, Khan K, Sadeghpour A, et al. Mutations in NCAPG2 Cause a Severe
353		Neurodevelopmental Syndrome that Expands the Phenotypic Spectrum of
354		Condensinopathies. Am J Hum Genet. 2019;104(1):94-111.
355	36.	Iqbal M, Maroofian R, Cavdarli B, et al. Biallelic variants in PCDHGC4 cause a novel
356		neurodevelopmental syndrome with progressive microcephaly, seizures, and joint
357		anomalies. Genet Med. 2021;23(11):2138-2149.
358	37.	Cousin MA, Creighton BA, Breau KA, et al. Pathogenic SPTBN1 variants cause an
359		autosomal dominant neurodevelopmental syndrome. Nat Genet. 2021;53(7):1006-1021.
360	38.	Harel T, Levy-Lahad E, Daana M, et al. Homozygous stop-gain variant in LRRC32,
361		encoding a TGFbeta receptor, associated with cleft palate, proliferative retinopathy, and
362		developmental delay. Eur J Hum Genet. 2019;27(8):1315-1319.
363	39.	Akita T, Aoto K, Kato M, et al. De novo variants in CAMK2A and CAMK2B cause
364		neurodevelopmental disorders. Ann Clin Transl Neurol. 2018;5(3):280-296.
365	40.	Dwyer BK, Veenma DCM, Chang K, Schulman H, Van Woerden GM. Case Report:
366		Developmental Delay and Acute Neuropsychiatric Episodes Associated With a de novo
367		Mutation in the CAMK2B Gene (c.328G>A p.Glu110Lys). Front Pharmacol.
368		2022;13:794008.
369	41.	Mannucci I, Dang NDP, Huber H, et al. Genotype-phenotype correlations and novel
370		molecular insights into the DHX30-associated neurodevelopmental disorders. Genome
371		Med. 2021;13(1):90.
372	42.	Romero-Ibarguengoitia ME, Cantu-Reyna C, Gutierrez-Gonzalez D, Cruz-Camino H,
373		Gonzalez-Cantu A, Sanz Sanchez MA. Comparison of Genetic Variants and
374		Manifestations of OTUD6B-Related Disorder: The First Mexican Case. J Investig Med
375		High Impact Case Rep. 2020;8:2324709620957777.
376	43.	Mizuguchi T, Nakashima M, Kato M, et al. Loss-of-function and gain-of-function
377		mutations in PPP3CA cause two distinct disorders. Hum Mol Genet. 2018;27(8):1421-
378		1433.
379	44.	Toro C, Hori RT, Malicdan MCV, et al. A recurrent de novo missense mutation in UBTF
380		causes developmental neuroregression. Hum Mol Genet. 2018;27(4):691-705.
381	45.	Sedlackova L, Lassuthova P, Sterbova K, et al. UBTF Mutation Causes Complex
382		Phenotype of Neurodegeneration and Severe Epilepsy in Childhood. Neuropediatrics.
383		2019;50(1):57-60.
384	46.	Cospain A, Schaefer E, Faoucher M, et al. Skraban-Deardorff syndrome: Six new cases
385		of WDR26-related disease and expansion of the clinical phenotype. Clin Genet.
386		2021;99(5):732-739.
387	47.	Pavinato L, Trajkova S, Grosso E, et al. Expanding the clinical phenotype of the ultra-
388		rare Skraban-Deardorff syndrome: Two novel individuals with WDR26 loss-of-function
389		variants and a literature review. Am J Med Genet A. 2021;185(6):1712-1720.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era


- 48. Carminho-Rodrigues MT, Steel D, Sousa SB, et al. Complex movement disorder in a
  patient with heterozygous YY1 mutation (Gabriele-de Vries syndrome). Am J Med Genet
  A. 2020;182(9):2129-2132.
- Juando-Prats C, James E, Bilder DA, et al. DRAVET ENGAGE. Parent caregivers of
  children with Dravet syndrome: Perspectives, needs, and opportunities for clinical
  research. Epilepsy Behav. 2021;122:108198.
- Solution Solution Collins C. Phenotype with a side of genotype, please: Patients, parents and priorities in rare genetic disease. Appl Transl Genom. 2016;8:42-44.
- 398 51. Girdea M, Dumitriu S, Fiume M, et al. PhenoTips: patient phenotyping software for clinical and research use. Hum Mutat. 2013;34(8):1057-1065.
- 400 52. Biesecker LG. An introduction to standardized clinical nomenclature for dysmorphic
  401 features: the Elements of Morphology project. BMC Med. 2010;8:56.
- 402 53. Elliott AM, Adam S, du Souich C, et al. Genome-wide sequencing and the clinical diagnosis of genetic disease: The CAUSES study. HGG Adv. 2022;3(3):100108.
- 404 54. Mak CC, Leung GK, Mok GT, et al. Exome sequencing for paediatric-onset diseases:
  405 impact of the extensive involvement of medical geneticists in the diagnostic odyssey.
  406 NPJ Genom Med. 2018;3:19.

It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

### 408 FIGURES

- 409 Figure 1. Global assessments of the quality of reporting of phenotype details germane to Domains
- 410 I-IV. Dark blue = initial reports (n=200 papers), and light blue = follow-up reports regarding the
- 411 25 genetic conditions initially described in 2017 (n=95 papers). There were no significant
- 412 differences in the distribution of overall quality ratings between the initial and follow-up reports,
- 413 for any of the domains (Fisher's exact tests, p>0.05). See text for details.



It is made available under a CC-BY-NC 4.0 International license .

AlMail, Jamjoom, et al. Phenotype reporting in the genomic era

- 414 **Figure 2.** Selected item-level findings from a systematic review of phenotype reporting in n=200
- 415 descriptions of novel genetic syndromes. Domain I, (b) Domain II, (c), Domain III. See 416 Supplementary Table 3 for details.

a)		% papers that always mention developmental issues n=194	4 b)		% papers that always mention growth n=118	
	Narrative descriptions always provided	21%		Actual growth measurements always reported	49%	
	Formal assessments always reported	10.5%		Two or more sets of post-birth measurements always reported	11%	
		% papers that always mention behavioural issues n=125			% papers reporting "feeding difficulties"	
	Details regarding assessment and type always reported	<b>5</b> %		Additional details provided for all individuals	8%	
	Treatment always mentioned	11%				
		% papers that specifically mention	c)	Individual's	% papers with phenotype that suggests a role for medications	n=173
	Vision Communication style	34%		medications listed	47%	
	or ability	33%		Efficacious drug trials	30%	
	Hearing	22%		mentioned Adverse effects	21%	
	Continence	0%		always mentioned		